- Conditions
- Refractory Multiple Myeloma
- Interventions
- Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration, Quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced May 22, 2026, 1:11 AM EDT